Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hepagam B Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The historical growth can be attributed to several factors, including the widespread global incidence of hepatitis B, the well-established utility of immune globulins, and the uptake by hospitals for managing exposures. Furthermore, shortcomings in vaccination programs and the inherent risks of occupational exposure also played a role.
The anticipated expansion during the forecast period is driven by more robust public health policies, enhanced safety measures for healthcare workers, an uptick in screening initiatives, the increase in hospital-administered prophylaxis, and worldwide efforts to eliminate hepatitis.
Significant trends expected over the forecast horizon encompass a heightened demand for post-exposure prophylaxis, a greater emphasis on safeguarding mothers and newborns, the expansion of immunoglobulin therapies, increasing public awareness regarding hepatitis B prevention, and more effective infection control protocols.
Get A Free Sample Report With In-Depth Market Insights:
Hepagam B Market Demand Drivers: What’s Powering Industry Growth?
The growing occurrence of hepatitis B is anticipated to propel the expansion of the hepagam B market in the future. Hepatitis B, a liver infection stemming from the hepatitis B virus (HBV), has the potential to progress to chronic illness, cirrhosis, or liver cancer. The upward trend in hepatitis B infections can be attributed to insufficient vaccination efforts, heightened spread among at-risk groups, and insufficient public understanding of prevention. HepaGam B offers a means to prevent hepatitis B infection by imparting passive immunity to individuals who have been exposed to the virus. For example, in April 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 254 million people globally were afflicted with chronic hepatitis B infection in 2022, with an additional 1.2 million new cases identified annually. This condition resulted in approximately 1.1 million deaths, predominantly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Consequently, the rising prevalence of Hepatitis B will be a driving force for the hepagam B market.
Hepagam B Market Segment Analysis: What Are The Core Market Categories?
The hepagam b market covered in this report is segmented –
1) By Product Type: Immunoglobulin Preparations, Vaccines, Antiviral Therapies
2) By Indication: Post-Exposure Prophylaxis, Chronic Hepatitis B Treatment
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Hepagam B Market Innovation Trends: What Developments Are Reshaping The Industry?
A primary trend in the hepagam B market involves expanding plasma collection centers to gain a competitive advantage. Plasma collection is the method of extracting plasma from a donor’s blood, utilized for diverse medical treatments, including the creation of immunoglobulins and clotting factor therapies. For instance, in September 2024, Kamada Limited, an Israel-based biopharmaceutical company, announced the launch of a new plasma collection center in Houston, Texas, aimed at enhancing its specialty plasma collection operations. This 12,000 square foot facility is designed to support over 50 donor beds and is expected to achieve an annual collection capacity of approximately 50,000 liters. The center will focus on collecting both normal source plasma and specialty plasma, projected to contribute an estimated $8 million to $10 million in annual revenue at full capacity. This expansion aligns with Kamada’s strategy to become a leading global player in the specialty plasma-derived market.
Hepagam B Market Top Companies Driving Competitive Growth
Major companies operating in the hepagam b market are Kamada Ltd., Kibiopharma Inc., Emergent BioSolutions Inc.
View The Full Hepagam B Market Report:
Hepagam B Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the hepagam B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepagam b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
